English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/169231
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorDíaz-Rodríguez, Elena-
dc.contributor.authorEl-Mallah, Al-Mahy-
dc.contributor.authorSanz, Eduardo-
dc.contributor.authorPandiella, Atanasio-
dc.date.accessioned2018-08-29T10:41:23Z-
dc.date.available2018-08-29T10:41:23Z-
dc.date.issued2017-
dc.identifierdoi: 10.3892/ol.2017.6440-
dc.identifiere-issn: 1792-1082-
dc.identifierissn: 1792-1074-
dc.identifier.citationOncology Letters 14(2): 1950-1958 (2017)-
dc.identifier.urihttp://hdl.handle.net/10261/169231-
dc.description.abstractHepatocellular carcinoma (HCC) is becoming one of the most prevalent types of cancer worldwide. The most efficient types of treatment at present include surgical resection and liver transplantation, but these treatments may only be used in a small percentage of patients. In order to identify novel therapeutic strategies for this disease, the present study explored the potential antitumoral effect of Ocoxin® oral solution (OOS) in HCC. OOS inhibited the proliferation of HCC cell lines in a time-and dose-dependent manner, being more efficient when used in combination with sorafenib, a standard of care treatment for patients diagnosed with advanced-stage disease. Mechanistic studies indicated that the effect of OOS was due to the induction of cell cycle arrest rather than the stimulation of apoptotic cell death. The cell cycle was slowed down in all phases in the HCC cell lines treated with OOS. Finally, when tested in animal models of HCC, OOS reduced tumor progression through the induction of necrosis in xenograft tumor models. Considering the poor prognosis and high resistance to antitumor treatments of HCC, the antiproliferative action of OOS, particularly in combination with sorafenib, provides the opportunity to investigate the effect of combined therapy in a clinical setting.-
dc.description.sponsorshipThe present study was supported by Catalysis S.L. and the Ministry of Economy and Competitiveness of Spain (grant no., BFU2012-39151). The present study was supported by a contract from the Spanish Cancer Network (grant no. AECC12/GC02). The Institute of Molecular and Cellular Cancer Biology (CSIC-University of Salamanca) laboratory received support from the European Community through the regional development funding program and from the Fundación Ramón Areces.-
dc.publisherSpandidos Publications-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectCell cycle-
dc.subjectAntioxidants-
dc.subjectHepatocellular carcinoma-
dc.titleAntitumoral effect of Ocoxin in hepatocellular carcinoma-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.3892/ol.2017.6440-
dc.relation.publisherversionhttps://doi.org/10.3892/ol.2017.6440-
dc.date.updated2018-08-29T10:41:23Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.rights.licensehttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderFundación Ramón Areces-
dc.contributor.funderEuropean Commission-
dc.contributor.funderAsociación Española Contra el Cáncer-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/100008054es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100003329es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.pmid28781639-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
anticarci.pdf1,41 MBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.